PALVELLA THERAPEUTICS, INC. (PVLA) FY2024 10-K Annual Report
PALVELLA THERAPEUTICS, INC. (PVLA) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 31, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
PALVELLA THERAPEUTICS, INC. FY2024 10-K Analysis
Risk Factors
- • Regulatory risk: FDA may require additional clinical trials for QTORIN rapamycin, increasing development costs and delaying approvals
- • Geopolitical risk: German R&D tax credit receivable of $2.0 million subject to changes in German tax laws and corporate reorganizations
PALVELLA THERAPEUTICS, INC. FY2024 Key Financial MetricsXBRL
Net Income
-$17M
▲ +29.0% YoY
ROE
-27.8%
▲ +6388bp YoY
Total Assets
$88M
▲ +128.1% YoY
EPS (Diluted)
$-7.83
▼ -460.8% YoY
Operating Cash Flow
-$11M
▲ +79.9% YoY
Source: XBRL data from PALVELLA THERAPEUTICS, INC. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on PALVELLA THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.